JP2023139070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023139070A5 JP2023139070A5 JP2023114120A JP2023114120A JP2023139070A5 JP 2023139070 A5 JP2023139070 A5 JP 2023139070A5 JP 2023114120 A JP2023114120 A JP 2023114120A JP 2023114120 A JP2023114120 A JP 2023114120A JP 2023139070 A5 JP2023139070 A5 JP 2023139070A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- car
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201770239 | 2017-03-31 | ||
| DKPA201770239 | 2017-03-31 | ||
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770542 | 2017-06-30 | ||
| DKPA201770542 | 2017-06-30 | ||
| EPPCT/EP2017/076800 | 2017-10-19 | ||
| PCT/EP2017/076800 WO2018073393A2 (en) | 2016-10-19 | 2017-10-19 | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| PCT/EP2018/058367 WO2018178377A1 (en) | 2017-03-31 | 2018-03-30 | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| JP2020503358A JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503358A Division JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023139070A JP2023139070A (ja) | 2023-10-03 |
| JP2023139070A5 true JP2023139070A5 (https=) | 2024-04-04 |
| JP7634045B2 JP7634045B2 (ja) | 2025-02-20 |
Family
ID=63674321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503358A Active JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
| JP2023114120A Active JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503358A Active JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11944643B2 (https=) |
| EP (3) | EP4414380A3 (https=) |
| JP (2) | JP7314115B2 (https=) |
| KR (1) | KR102726269B1 (https=) |
| CN (1) | CN110869046B (https=) |
| AU (2) | AU2018246377B2 (https=) |
| BR (1) | BR112019020203A2 (https=) |
| CA (1) | CA3058268A1 (https=) |
| DK (1) | DK3592379T3 (https=) |
| ES (1) | ES2979232T3 (https=) |
| IL (1) | IL269538B2 (https=) |
| MX (1) | MX2019011475A (https=) |
| PT (1) | PT3592379T (https=) |
| WO (2) | WO2018178377A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190161530A1 (en) * | 2016-04-07 | 2019-05-30 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| CA3038532A1 (en) | 2016-10-05 | 2018-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin compounds and methods of preparing the same |
| AU2018246377B2 (en) * | 2017-03-31 | 2025-01-30 | Cellectis Sa | Universal anti-CD22 chimeric antigen receptor engineered immune cells |
| JP2020537515A (ja) | 2017-10-03 | 2020-12-24 | ジュノー セラピューティクス インコーポレイテッド | Ｈｐｖ特異的結合分子 |
| EP3774919A4 (en) * | 2018-03-30 | 2021-12-29 | Eureka Therapeutics, Inc. | Constructs targeting cd22 and uses thereof |
| CA3094468A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| CN113454117B (zh) | 2018-12-19 | 2025-07-04 | 宾夕法尼亚大学董事会 | Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途 |
| SG11202111031RA (en) * | 2019-04-26 | 2021-11-29 | Allogene Therapeutics Inc | Rituximab-resistant chimeric antigen receptors and uses thereof |
| EP3972585A4 (en) * | 2019-05-21 | 2023-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin compounds for enhancement of immunotherapy |
| EP4127188A4 (en) * | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| GB202007842D0 (en) * | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| CA3186325A1 (en) * | 2020-07-31 | 2022-02-03 | Andre Choulika | Dual car-t cells |
| CN111944850B (zh) * | 2020-08-28 | 2023-03-31 | 澳门大学 | 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用 |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022177961A1 (en) * | 2021-02-16 | 2022-08-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i–restricted t cell receptors against cd22 |
| KR102829757B1 (ko) * | 2021-11-17 | 2025-07-09 | (주)이노베이션바이오 | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 |
| EP4452319A1 (en) * | 2021-12-22 | 2024-10-30 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for delivery of therapeutic agents to acceptor cells |
| CN118359729A (zh) * | 2023-01-19 | 2024-07-19 | 武汉昭智生物技术有限公司 | 一种car分子、包含其的细胞或外泌体及它们的应用 |
| WO2025049961A1 (en) * | 2023-09-01 | 2025-03-06 | Cargo Therapeutics, Inc. | Anti-cd22 chimeric antigen receptor (car) therapies |
| WO2025212803A2 (en) * | 2024-04-03 | 2025-10-09 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd22 chimeric antigen receptors |
| CN119775433B (zh) * | 2024-12-09 | 2025-11-28 | 吉林大学第一医院 | 一种细胞膜表达的il-15融合蛋白及其在细胞治疗中的应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6060505A (en) | 1996-03-20 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating cancer using C-26 modified bryostatin |
| JP2001522244A (ja) | 1997-04-24 | 2001-11-13 | ユニバーシティ オブ ワシントン | パルボウイルスベクターによる標的化した遺伝子改変 |
| AU784589B2 (en) | 1999-11-30 | 2006-05-04 | Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| WO2008100450A2 (en) | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126720A2 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| BR112014029417B1 (pt) * | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| MX367730B (es) | 2012-09-04 | 2019-09-04 | Cellectis | Receptor de antigeno quimerico multi-cadena y usos del mismo. |
| RU2658485C2 (ru) | 2012-10-24 | 2018-06-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы м971 |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| WO2015075195A1 (en) | 2013-11-22 | 2015-05-28 | Cellectis | Method of engineering chemotherapy drug resistant t-cells for immunotherapy |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| WO2015121454A1 (en) | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| JP6681837B2 (ja) | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| PL3119807T3 (pl) * | 2014-03-19 | 2019-09-30 | Cellectis | Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów |
| EP3131927B8 (en) * | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| WO2016124765A1 (en) * | 2015-02-06 | 2016-08-11 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| US10738116B2 (en) * | 2015-03-19 | 2020-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors |
| AU2016243583B2 (en) * | 2015-03-27 | 2022-03-10 | President And Fellows Of Harvard College | Modified T cells and methods of making and using the same |
| CN108026526B (zh) | 2015-06-09 | 2023-05-12 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| CN105958210B (zh) | 2016-05-06 | 2018-10-30 | 中国科学院国家天文台 | Fast望远镜开孔式反射面单元及其开孔方法 |
| CN105968210B (zh) * | 2016-05-13 | 2019-05-31 | 深圳生创精准医疗科技有限公司 | 靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途 |
| AU2017291851B2 (en) | 2016-07-06 | 2022-10-13 | Cellectis | Sequential gene editing in primary immune cells |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| WO2018073394A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| AU2018246377B2 (en) * | 2017-03-31 | 2025-01-30 | Cellectis Sa | Universal anti-CD22 chimeric antigen receptor engineered immune cells |
| CA3067914A1 (en) * | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| EP4185616A1 (en) * | 2020-07-24 | 2023-05-31 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
-
2018
- 2018-03-30 AU AU2018246377A patent/AU2018246377B2/en active Active
- 2018-03-30 ES ES18715024T patent/ES2979232T3/es active Active
- 2018-03-30 AU AU2018246378A patent/AU2018246378A1/en not_active Abandoned
- 2018-03-30 US US16/498,899 patent/US11944643B2/en active Active
- 2018-03-30 US US16/498,276 patent/US11690873B2/en active Active
- 2018-03-30 WO PCT/EP2018/058367 patent/WO2018178377A1/en not_active Ceased
- 2018-03-30 BR BR112019020203-0A patent/BR112019020203A2/pt unknown
- 2018-03-30 WO PCT/EP2018/058368 patent/WO2018178378A1/en not_active Ceased
- 2018-03-30 PT PT187150248T patent/PT3592379T/pt unknown
- 2018-03-30 DK DK18715024.8T patent/DK3592379T3/da active
- 2018-03-30 CA CA3058268A patent/CA3058268A1/en active Pending
- 2018-03-30 KR KR1020197032371A patent/KR102726269B1/ko active Active
- 2018-03-30 EP EP24166930.8A patent/EP4414380A3/en active Pending
- 2018-03-30 MX MX2019011475A patent/MX2019011475A/es unknown
- 2018-03-30 EP EP18715024.8A patent/EP3592379B1/en active Active
- 2018-03-30 CN CN201880036267.2A patent/CN110869046B/zh active Active
- 2018-03-30 JP JP2020503358A patent/JP7314115B2/ja active Active
- 2018-03-30 EP EP18715025.5A patent/EP3592380B1/en active Active
-
2019
- 2019-09-23 IL IL269538A patent/IL269538B2/en unknown
-
2023
- 2023-07-12 JP JP2023114120A patent/JP7634045B2/ja active Active
- 2023-12-21 US US18/393,322 patent/US12133867B2/en active Active
-
2024
- 2024-09-26 US US18/898,069 patent/US20250026808A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023139070A5 (https=) | ||
| JP6968389B2 (ja) | Ｂｃｍａに結合するキメラ抗原受容体（ｃａｒ）及びその応用 | |
| CN111527109B (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2020512019A5 (https=) | ||
| JP2022109953A5 (https=) | ||
| JP2023053328A5 (https=) | ||
| JP2020022508A (ja) | 細胞 | |
| JP2020096630A5 (https=) | ||
| JP2021531004A5 (https=) | ||
| JP2023514407A5 (https=) | ||
| JP2020530989A5 (https=) | ||
| JP2017537627A5 (https=) | ||
| CN107406517A (zh) | 包含cd19结合域的嵌合抗原受体(car) | |
| JP2017500869A5 (https=) | ||
| CN110144012A (zh) | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 | |
| CN109789164B (zh) | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 | |
| JP2022542559A5 (https=) | ||
| CN113045657B (zh) | 一种人源化抗人bcma单克隆抗体及其car-t细胞 | |
| JP2023545907A (ja) | 新規共刺激ドメインを含むキメラ抗原受容体及びその使用 | |
| JP2024505955A (ja) | 新型キメラ抗原受容体及びその使用 | |
| CN114249832B (zh) | 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用 | |
| CN110724199A (zh) | Nkg2d car-t细胞及其制备和应用 | |
| CN107663240A (zh) | Mg7，高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 | |
| JP2025513607A (ja) | Ｃｄ７遺伝子がノックアウトされた操作された免疫細胞及びその用途 | |
| WO2020172643A2 (en) | Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same |